Liraglutide Injection
Product Images NDC 70748-346

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 70748-346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 1)

An instructional illustration showing a person holding and preparing a Liraglutide injection pen. The image focuses on the hands interacting with the pen, indicating steps for use such as twisting or removing a cap.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 10)

An instructional illustration showing a close-up of a hand pressing a button or plunger on a pen-injector device, demonstrating the operation of the injection mechanism, likely related to administering Liraglutide subcutaneous injection.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 11)

An instructional illustration showing a close-up of a person preparing a prefilled syringe injection. The image highlights the step of attaching or securing the needle cap before use, indicated by an arrow pointing towards the needle cap area of the syringe.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 12)

An instructional diagram illustrating the injection process for Liraglutide. It shows an arrow pointing to the left labeled 'K', directing a vial and syringe with a droplet at the needle tip, and a hand with a forefinger and thumb preparing to press a button or cap.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 13)

An instructional diagram showing a dial on a Liraglutide injection pen for subcutaneous use. The dial displays dose options of 0.6 mg, 1.2 mg, and 1.8 mg with corresponding labels indicating each dose selected.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 14)

An instructional illustration showing recommended injection sites for subcutaneous administration of Liraglutide injection. The marked areas include the upper arms, stomach, and thigh on a simplified human figure.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 15)

An instructional illustration showing a hand pressing down on the cap of a liraglutide injection pen. A label on the pen indicates a dose of 0 mg, suggesting it depicts the initial step or a dose-setting action for subcutaneous administration.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 16)

An instructional illustration showing a hand holding a Liraglutide injection pen with an arrow indicating pressing down on the skin for subcutaneous injection. A timer icon displaying "6" suggests the injection duration in seconds.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 17)

An instructional illustration showing a subcutaneous injection pen with an arrow pointing upwards, indicating the direction or step to be followed in preparing or administering the injection of liraglutide 6 mg/mL by Lupin Pharmaceuticals, Inc.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 18)

An instructional illustration showing a close-up of two parts of an injection device. The left component, likely the needle cap, is connected to the main pen injector on the right. An arrow points left, indicating the direction to remove or detach the needle cap from the pen injector.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 19)

Instructional illustration showing a hand removing the cap from a Liraglutide injection pen. The image demonstrates the correct technique for preparing the subcutaneous injection device before use.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 2)

An instructional illustration depicting a hand holding an injection pen device. The image focuses on the mechanism for dose setting or delivery, highlighting the interaction with a dose-selection dial or button on the pen. The background is minimal and the style is simple line art with blue accents.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 3)

An instructional illustration showing a step in using a pre-filled injection pen. It depicts a close-up of a hand holding the pen and preparing to attach or remove a needle by turning it clockwise or counterclockwise as indicated by an arrow.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 4)

An instructional illustration showing how to prepare a dose with a Liraglutide injection pen. It depicts a hand holding the pen, pressing a button, and the needle being positioned for subcutaneous injection.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 5)

Liraglutide injection carton from Lupin Pharmaceuticals, Inc. The label shows Liraglutide 6 mg/mL subcutaneous injection. The packaging includes a vial with scale markings and safety information on the carton flap. The product NDC code is 70748-346.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 6)

An instructional illustration showing a hand holding a pen-like injection device with a label displaying '0 mg'. Below, a flow check symbol is highlighted, with accompanying text stating 'Flow check symbol selected.' The image indicates part of the usage or preparation process for a subcutaneous injectable drug device.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 7)

An instructional illustration showing a hand about to push down on the top of a syringe or injection pen, indicating the action of pressing to administer the injection. The image emphasizes the use of a needle for subcutaneous injection.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 8)

An instructional diagram showing a person holding a Liraglutide injection pen for subcutaneous use. The image demonstrates the preparation step of the injection device, with an inset focusing on the needle cap being removed. An arrow indicates the upward pulling action required to remove the cap.*

FDA Label Image

Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 9)

An instructional illustration showing hands removing a cap or cover from the top of an injection pen device, indicated by directional arrows. The image likely guides proper preparation of a subcutaneous injection pen for use.*

FDA Label Image

Image (673a6213 Cf00 4aba Bcf7 47954d59231e 01)

Illustration showing the peptide sequence of liraglutide, highlighting a C-16 fatty acid (palmitoyl) modification attached to a glutamic acid (Glu) residue. The amino acids are represented in a chain with three-dimensional folding indicated by arrows, emphasizing the structural features of the liraglutide molecule.*

FDA Label Image

Image (673a6213 Cf00 4aba Bcf7 47954d59231e 02)

A line graph comparing insulin secretion rate (ISR) in pmol/kg/min versus plasma glucose levels in mg/dL for Liraglutide Injection and Placebo. Liraglutide Injection shows a higher ISR that increases more steeply with rising plasma glucose compared to Placebo, which shows a lower and less steep increase in ISR.*

FDA Label Image

Image (673a6213 Cf00 4aba Bcf7 47954d59231e 03)

A line graph comparing mean HbA1c percentages over time (up to 52 weeks) for groups receiving Liraglutide Injection at 1.2 mg and 1.8 mg doses, Glimepiride, and Placebo. The x-axis represents time in weeks, and the y-axis shows mean HbA1c percentage values. The graph includes statistical significance notes for comparisons between treatment groups.*

FDA Label Image

Image (673a6213 Cf00 4aba Bcf7 47954d59231e 04)

A line graph comparing mean HbA1c percentages over 26 weeks among three treatments: Liraglutide Injection 1.2 mg, Liraglutide Injection 1.8 mg, and Sitagliptin 100 mg. The graph shows a decrease in mean HbA1c for both liraglutide doses compared to sitagliptin, with statistical significance indicated. Time is plotted on the x-axis and mean HbA1c (%) on the y-axis.*

FDA Label Image

Image (673a6213 Cf00 4aba Bcf7 47954d59231e 05)

Illustration diagram of the Liraglutide pen injection device showing labeled parts including pen cap, rubber stopper, cartridge scale, cartridge tip, pointer, dose display, dose button, and dose selector. Below are depictions of needle protective shields labeled outer shield, inner shield, needle, and tab, providing a visual guide for assembly or use.*

FDA Label Image

Img 1 (673a6213 Cf00 4aba Bcf7 47954d59231e 06)

Packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection by Lupin Pharmaceuticals, Inc. The label shows a box containing 2 prefilled injection pens. The label includes dosage instructions, storage directions (refrigerate, do not freeze), and manufacturer details for Lupin Pharmaceuticals, Inc. and Lupin Limited in India. Usage is Rx only, for single patient use.*

FDA Label Image

Img 2 (673a6213 Cf00 4aba Bcf7 47954d59231e 07)

Packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection, supplied in a box containing 3 prefilled pens. Labeler is Lupin Pharmaceuticals, Inc. It includes dosing instructions, storage requirements (refrigerate, do not freeze), and manufacturing details indicating production in China and India.*

FDA Label Image

Image (673a6213 Cf00 4aba Bcf7 47954d59231e 163 2)

Liraglutide 6 mg/mL injection vial label from Lupin Pharmaceuticals, Inc. The label shows the product name, strength, route (subcutaneous), and features a floral design pattern at the bottom. The vial is clear glass with a gray cap and a white label.*

FDA Label Image

Image (Dfd8faeb 066c 4938 9833 Fabc2dd3c94b 142 1)

Liraglutide 6 mg/mL injection is shown in a cartridge pack with a clear plastic blister. The label indicates the product is manufactured by Lupin Pharmaceuticals, Inc. The packaging displays multiple cartridges arranged in a cross pattern with printed information visible on each cartridge label.*

FDA Label Image

Image (Dfd8faeb 066c 4938 9833 Fabc2dd3c94b 156 1)

Liraglutide 6 mg/mL injection vial label from Lupin Pharmaceuticals, Inc. The label provides product identification including the proprietary and generic name, concentration strength, and route of administration (subcutaneous). The label is primarily yellow and white with black text and a purple circular logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.